SGPNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
SpyGlass Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$24.60+0.60 (+2.50%)
Close on Oct 19, 2026
- Market cap
- $822.61M
- P/E (TTM)
- –
- Dividend yield
- –
SpyGlass Pharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | SpyGlass Pharma | Industry median |
|---|---|---|
| Market Cap | $822.82M | $230.55M |
| Enterprise Value | $599.68M | $202.97M |
| PB Ratio | 3.54 | 3.04 |
| P/TBV Ratio | 3.54 | 4.43 |
Income (trailing twelve months)
| Measure | SpyGlass Pharma | Industry median |
|---|---|---|
| Operating Income | -$41.45M | -$4.31M |
| Pretax Income | -$39.87M | -$2.37M |
| Net Income | -$39.87M | -$6.57M |
| EBITDA | -$41.45M | -$1.98M |
| EPS (Diluted) | -$17.98 | -$0.08 |
Returns
| Measure | SpyGlass Pharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -51.8% | -18.2% |
| Return on Assets (ROA) | -16.4% | -13.3% |
| Return on Capital Employed (ROCE) | -17.7% | -9.07% |
Balance sheet
| Measure | SpyGlass Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $223.14M | $36.66M |
| Net Cash (Debt) | $223.14M | $3.92M |
| Net Cash Per Share | $6.67 | $0.28 |
| Equity (Book Value) | $232.36M | $55.33M |
| Book Value Per Share | $6.95 | $2.87 |
| Tangible Book Value | $232.36M | $10.79M |
| Working Capital | $227.02M | $56.72M |
Financial position
| Measure | SpyGlass Pharma | Industry median |
|---|---|---|
| Current Ratio | 25.06 | 2.48 |
| Quick Ratio | 23.65 | 1.53 |
Cash flow (trailing twelve months)
| Measure | SpyGlass Pharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$32.70M | -$566.22K |
| Capital Expenditures | -$789.00K | -$3.69M |
| Free Cash Flow | -$33.49M | -$696.00K |
| FCF Per Share | -$1.00 | -$0.02 |
Efficiency
| Measure | SpyGlass Pharma | Industry median |
|---|---|---|
| Profits Per Employee | -$613.37K | -$51.88K |
| Employee Count | 65 | 185 |
Dividends and yields
| Measure | SpyGlass Pharma | Industry median |
|---|---|---|
| Earnings Yield | -4.85% | -6.88% |
| FCF Yield | -4.07% | -0.45% |
| Buyback Yield | 0.18% | 0.78% |
| Shareholder Yield | 0.18% | 0.80% |
Shares
| Measure | SpyGlass Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 33,448,000 | 44,302,700 |
| Shares Change (YoY) | 24.0% | 3.36% |
| Shares Change (QoQ) | 0.04% | 0.27% |
| Float | 11,101,800 | 37,462,700 |
| Shares Held by Insiders | 66.8% | 10.5% |
| Shares Held by Institutions | 78.1% | 63.5% |
Taxes
| Measure | SpyGlass Pharma | Industry median |
|---|---|---|
| Income Tax | $0 | $1.52M |
Scores
| Measure | SpyGlass Pharma | Industry median |
|---|---|---|
| Altman Z-Score | 44.36 | 1.95 |
| Piotroski F-Score | 4 | 5 |
Calculated by StockData from SpyGlass Pharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.